DRI Healthcare Trust Overview
Correction to input identification details. The input list gives the country as Bermuda. That is not accurate for the listed issuer. DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario, Canada, and it is headquartered in Toronto (source: IPO closing disclosure, February 2021).
The Bermuda tag may refer to the domicile of a subsidiary or of a historical DRI fund vehicle. The Trust's operating subsidiaries that were identified in disclosures are DRI Healthcare LP, which issued the 2026 Senior Secured Notes, and DRI Healthcare Acquisitions LP, the counterparty on the Viridian deal.
DRI Healthcare Trust is a specialist pharmaceutical royalty acquirer. It is the only publicly listed pure-play drug-royalty vehicle on the TSX, and it reports in U.S. dollars. It buys contractual rights to a share of the net sales of approved, or near-approved, branded medicines. It then collects high-margin, largely passive cash flows that are marketed by large-cap biopharma counterparties such as Menarini, Biogen, Roche/Novartis, Regeneron/Bayer, Sanofi and Vertex.
The franchise traces back to DRI Capital's founding in 1989. Across that history, the platform has deployed more than $3.0 billion to acquire more than 75 royalties on more than 50 drugs.
Since internalizing its manager in 2025, the Trust has re-rated its cost base. Its Adjusted EBITDA margin rose to 91–92% in recent quarters. It has also moved into synthetic and pre-approval royalties, including Ekterly, Lumvoa and Juvmo, to source growth.
Its scale is about $200M of annual total income. That makes it a nimble mid-cap alternative to Royalty Pharma, but one with materially higher single-asset concentration, chiefly Orserdu and Omidria.
Company's own description
DRI describes itself as a pioneer in global pharmaceutical royalty monetization. It cites more than $3.0 billion deployed since 1989 across more than 75 royalties on more than 50 drugs. Named historical and current royalties include Ekterly, Eylea, Keytruda, Lumvoa (veligrotug), Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga (boilerplate, Q2 2026 release, August 7, 2026).
The Trust's IPO-era description framed the vehicle as giving unitholders differentiated exposure to the anticipated growth of the global pharmaceutical and biotechnology markets (IPO disclosure, February 2021).
Business model
DRI generates income by acquiring three kinds of interest:
Traditional royalties: These are existing royalty streams owned by inventors, universities or biotechs that out-licensed a drug. Examples are Spinraza, Eylea, Xolair, Zytiga and Orserdu I/II.
Synthetic royalties: These are newly created royalties carved out of a developer's own product sales in exchange for upfront capital. Examples are Ekterly/sebetralstat with KalVista, veligrotug/VRDN-003 with Viridian, and Vonjo with CTI BioPharma, which was paired with a secured loan.
Structured payment streams: These are contractual licence-fee and milestone streams. Examples are the Casgevy licence fees acquired from Editas Medicine, and the Juvmo (tavapadon) package of fixed annual payments, tiered royalties and sales milestones, subject to a hard cap.
Revenue model
There is no product, service or subscription revenue. Total income consists of four items:
-
Royalty income from intangible royalty assets. This is accrued on underlying sales and collected on a contractual lag, commonly one quarter. Xenpozyme and Zytiga are collected semi-annually, and Empaveli/Syfovre on a three-quarter lag.
-
Changes in the fair value of financial royalty assets, such as Casgevy.
-
Milestone royalty income.
-
Interest and other income, including gains on marketable securities.
Value-chain position
DRI is a capital provider that sits between drug developers and marketers on one side and public-market investors on the other. It takes no clinical, manufacturing or commercial execution risk directly. It does take product-performance, patent-life, competitive and counterparty-reporting risk.
Customers and counterparties
DRI's "customers" are the sellers of royalties: inventors, academic institutions, biotechs, and private funds such as Bain Capital and NovaQuest in the tavapadon deal. Cash is paid by the marketers.
End-markets
The end-markets are global branded prescription pharmaceuticals across oncology, ophthalmology, hematology, neurology, immunology, lysosomal storage disorders, dermatology and endocrinology.
Independent characterization
DRI is best understood as a levered, high-cash-margin annuity portfolio with a finite and depleting asset life. Every royalty amortizes toward expiry, so growth depends entirely on redeploying cash at returns above its cost of capital.
The 2025 internalization removed the external-manager fee leakage, which was $11.4M in management fees in FY2024. It also aligned incentives through a new Carried Interest Plan.
The strategic pivot toward pre-approval and synthetic deals raises potential IRRs, as the 1.5x, high-20s-IRR Ekterly exit shows. It also raises binary regulatory risk.
Strategy
Stated strategy themes
Management's language from FY2025 and 2026 centres on four themes:
-
2025 as an "inflection point" following internalization;
-
2026 as a foundational year for a new multi-year growth agenda;
-
building a model for "durable compounding growth";
-
disciplined underwriting across the full lifecycle of an asset, from regulatory approval to realized returns.
Initiatives in the last 24 months
| Initiative | Date | Detail / target |
|---|---|---|
| Internalization of manager | Announced May 2025, closed July 2025 | $49M total cost (about 4x trailing management fees). Expected synergies of $200M over 10 years. Management said benefits were "pacing ahead of schedule" in Q4 2025. |
| Pre-approval royalty strategy | 2024–2026 | Ekterly (approved and exited at 1.5x) and Lumvoa (approved June 2026). |
| Capital structure optimization | Mar 2026 | $250M Senior Secured Notes: $106M at 5.35% due 2031 and $144M at 5.65% due 2033. Preferred securities exchanged into C$108.7M of 5.75% convertible debentures due 2031. |
| Carried Interest Plan | Approved May 2026 | Aligns the investment team with realized returns |
| Unitholder returns | Ongoing | Distribution raised to $0.11 per quarter for 2026. The 2026 NCIB allows up to 3.06M units. More than $36M was returned in 2025. |
| Board refresh | Aug 2026 | Added clinical and biotech-finance expertise (Singh, Al-Wakeel) |
| Tavapadon acquisition | Sep 2026 | $316M. Management said this deal alone could deliver the 2030 Adjusted EBITDA aspiration even without further acquisitions. |
Medium-term targets
| Item | Target |
|---|---|
| 2026 Adjusted EBITDA guidance | $157M–$162M, against a 2025 run-rate baseline of $149.2M. The baseline removes $15.7M of non-recurring Orserdu back-royalties. |
| Updated 2026 view (Q2 2026 call) | Expect to meet or exceed the high end of guidance |
| Capital deployment, 2026–2030 | $800M–$1,000M |
| Adjusted EBITDA growth, 2026–2030 | Low-teens CAGR. Described as an aspiration, not formal guidance. |
| Prior five-year target (2021–2025) | $1.25B deployment, described as achieved on a committed basis including contingent milestones |
ESG and sustainability commitments
No ESG commitments, emissions targets or ESG ratings were identified in the sources reviewed (not publicly disclosed).
Products & Services
DRI sells no products. Its "portfolio" is its royalty and payment-stream assets.
As of June 30, 2026, the portfolio held 28 royalty streams on 22 products (Q2 2026 release). This is before the Ekterly exit and the Lumvoa and Juvmo additions.
Oncology
| Asset | Description | Marketer | DRI entry / cost | Royalty economics (as disclosed) |
|---|---|---|---|---|
| Orserdu I (elacestrant) | Oral SERD for ESR1-mutated advanced or metastatic breast cancer | Menarini (Stemline) | 2023, from Eisai, $85M | Running royalty plus milestones. A $5.0M milestone was received in H1 2026. |
| Orserdu II (elacestrant) | Second royalty stream on the same product | Menarini | Aug 2023, from Radius Health, $130M plus up to $40M in milestones | Deductions were removed in 2025, giving a higher effective rate. About $17.6M of back-dated reclamations was received in Q1 2025. |
| Rydapt (midostaurin) | FLT3 inhibitor for AML and systemic mastocytosis | Novartis | IPO portfolio (2021) | Not detailed |
| Zejula (niraparib) | PARP inhibitor for ovarian cancer | GSK | Q3 2022, from AnaptysBio, $35M | About 0.5% net royalty on worldwide sales. A $10M milestone was tied to an endometrial cancer approval. |
| Zytiga (abiraterone) | Prostate cancer | Johnson & Johnson | IPO portfolio | Received semi-annually. Mature and declining. |
Ophthalmology
| Asset | Description | Marketer | Entry / cost | Economics |
|---|---|---|---|---|
| Omidria (phenylephrine/ketorolac) | Intracameral use in cataract and lens-replacement surgery | Rayner Surgical | Sep 30, 2022, from Omeros, $125M (capped). Expanded Feb 1, 2024 for $115M plus up to $55M in milestones. | The 2022 tranche had annual caps ($25M a year for 2025–2028). The 2024 expansion gave DRI the remainder of Omeros' U.S. royalties. A $9.7M impairment was taken in Q4 2025. |
| Eylea I and Eylea II (aflibercept) | Anti-VEGF for retinal disease | Regeneron, Bayer, Santen | IPO portfolio | Contractual step-downs. Some Q1 2026 cash was held in escrow and released in June 2026. |
Hematology
| Asset | Description | Marketer | Entry / cost | Economics |
|---|---|---|---|---|
| Vonjo I and II (pacritinib) | JAK2/IRAK1 inhibitor for myelofibrosis | Sobi | 2022 (CTI: $50M loan, $60M royalty, $6.5M milestone). Vonjo II added in Q2 2023 for $66M. | Vonjo II was impaired by $13.7M in Q3 2025, consistent with Sobi's own write-down. |
| Casgevy (exa-cel) | CRISPR gene-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia | Vertex | Oct 3, 2024, from Editas, $57M | DRI receives a share of annual licence fees (range of $5M–$40M) and a mid-double-digit percentage of Editas' share of a $50M contingent payment. The term runs to 2034. Accounted for as a financial royalty asset. |
| Empaveli/Syfovre (pegcetacoplan) | Complement C3 inhibitor for PNH (Empaveli) and geographic atrophy (Syfovre) | Apellis, Sobi | Q3 2022, $24.5M plus a $21M option. A $3.7M add-on followed in 2023. | Royalty below 1% on worldwide sales up to $500M. Cash is received on a three-quarter lag. |
Neurology
| Asset | Description | Marketer | Entry / cost | Economics |
|---|---|---|---|---|
| Spinraza (nusinersen) | Antisense therapy for spinal muscular atrophy | Biogen | IPO portfolio | Steady at about $15M a year |
| Juvmo (tavapadon) — new | Once-daily oral selective D1/D5 partial agonist for Parkinson's disease motor symptoms | AbbVie (inferred from its 2024 Cerevel acquisition; DRI's release does not name the marketer) | Agreement Sep 21, 2026, $316M from Bain Capital and NovaQuest funds. Closing expected Sep 29, 2026 (completion not confirmed in the sources reviewed). | Four fixed payments of $23.4M on the first four anniversaries of approval (from September 25, 2027). Tiered mid-single-digit to low-double-digit royalties on U.S. net sales, plus sales milestones. Aggregate receipts are hard-capped at $437.5M. |
Immunology
| Asset | Description | Marketer | Entry / cost | Economics |
|---|---|---|---|---|
| Xolair (omalizumab) | Anti-IgE for asthma, chronic urticaria and food allergy | Roche, Novartis | — | Growing: $12.6M of receipts in FY2025, up 18% |
| Ekterly (sebetralstat) — exited | First oral on-demand therapy for hereditary angioedema | KalVista, now Chiesi | Nov 2024, $100M plus a $22M option, for $127M total | Royalty was 6% on sales up to $500M after the option was exercised. The put was exercised July 2026, returning about $178M. |
Other therapeutic areas
| Asset | Area | Marketer | Notes |
|---|---|---|---|
| Xenpozyme (olipudase alfa) | Lysosomal storage disorder (ASMD) | Sanofi | $30M in Q4 2022 for about 1% of worldwide sales over about 15 years. A second royalty was later acquired from HLS Therapeutics. Paid semi-annually. |
| Oracea (doxycycline) | Dermatology (rosacea) | Galderma | Mature and declining |
| Natpara | Endocrinology | Takeda | Product discontinued; royalty in run-off |
| Lumvoa (veligrotug) and elegrobart (VRDN-003) — new | Thyroid eye disease | Viridian | Synthetic royalty on U.S. net sales. $55M upfront, plus a $75M approval milestone paid July 10, 2026. The maximum remaining milestone obligation was $130M as of Q2 2026. Disclosed tiers include 0.8% on sales between $600M and $900M and 0.25% on sales between $900M and $2B, with no royalty above $2B. |
Financial Narrative
Basis of preparation. Figures are IFRS, in USD millions, for fiscal years ending December 31.
Concepts that do not apply. Gross profit, operating income and capex are not meaningful for a royalty trust and are not reported as such. Total income is the top-line equivalent. DRI's primary performance metrics are non-GAAP: Total Cash Receipts, Adjusted EBITDA and Adjusted Cash Earnings per Unit.
Income statement and per-unit data
Notes on the table:
-
FY2021 Total Cash Receipts is presented on a pro forma basis, because it includes cash received by subsidiaries before the IPO acquisition.
-
FY2021 total income is labelled "royalty income and interest income."
-
FY2023 includes a $109.6M net gain on the Tzield sale.
-
FY2025 includes the $48.0M internalization termination fee.
-
The FY2025 distribution of $0.40 is four quarterly payments of $0.10, consistent with $22.2M declared on 55.7M weighted units.
-
From Q1 2026 the quarterly distribution is $0.11.
Margins and growth
Notes: the FY2021 margin is pro forma. The FY2023 net margin uses comprehensive earnings.
Revenue CAGR. Total income compounded at 24.8% a year from FY2021 to FY2025, rising from $81.8M to $198.6M. From FY2022 to FY2025 the CAGR was 28.8%.
Interim trend (latest)
Q1 2026 figures are derived as H1 2026 minus Q2 2026.
LTM total income at June 30, 2026 was $209.2M (Q2 2026 call).
Balance sheet
Royalty assets carry no goodwill. The royalty portfolio is held as intangible assets, with a small financial asset component (Casgevy).
Post-year-end capital structure (June 30, 2026). Cash was $55.2M. Long-term debt was $372.3M, made up of:
-
$29.1M long-term portion of the credit facility;
-
$31.0M of remaining preferred securities;
-
$64.8M of convertible debentures (carrying value);
-
$247.4M of senior notes.
Intangible royalty assets were $808.9M and financial royalty assets $55.6M.
Subsequent events change this picture materially:
-
The company drew $50M under the facility on July 9, 2026 and paid the $75M Viridian milestone.
-
About $178M of Ekterly proceeds were received on August 11, 2026.
-
The $316M tavapadon purchase was funded with cash on hand plus credit-facility borrowings, with closing expected September 29.
Pro forma Q3 2026 leverage is not yet publicly disclosed.
Cash flow and capital returns
Notes: the FY2021 deployment figure is the IPO portfolio. FY2025 deployment excludes $115M of near-term contingent Viridian commitments. Capex is immaterial for this model.
Ratios
ROE, ROA, ROIC, current ratio, debt/equity, asset turnover and cash conversion cycle are not computed. Equity and total-asset figures were not available in the sources reviewed. A cash conversion cycle does not apply to a royalty trust.
Commentary
Top line. Growth has been step-function and driven by acquisitions:
-
FY2022 benefited from the Vonjo, Empaveli, Zejula, Omidria and Xenpozyme deals ($281M deployed).
-
FY2023 was inflated by the $109.6M Tzield gain.
-
FY2024 and FY2025 reflect full-year Orserdu economics, the Omidria expansion and the Casgevy contribution.
Organic growth. Underlying growth is more modest. Management cited royalty income rising from $41.0M in Q2 2024 to $48.2M in Q2 2026, about 18% cumulatively over two years.
Net earnings. IFRS net earnings are structurally depressed by about $100M a year of amortization. They are made volatile by impairments ($15.8M in FY2024 and $23.4M in FY2025) and one-offs, notably the $48.0M termination fee in FY2025.
Cash earnings. Adjusted Cash EPU is the better gauge. It was $1.85 in FY2021, $2.53 in FY2023 including the Tzield effect, $2.18 in FY2024 and $2.26 in FY2025. It reached $1.24 in H1 2026, versus $0.95 in H1 2025.
Margin inflection. Internalization moved the Adjusted EBITDA margin from 76% in Q2 2025 to 92% in Q2 2026. Management guides to high-80s to 90% for H2 2026.
Capital structure. The 2026 refinancing shifted the debt stack from an amortizing bank facility toward fixed-rate notes due 2031 and 2033. That lowers annual debt amortization.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Therapeutic area (Cash receipts, USD Mn) | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|
Oncology (Orserdu I+II, Rydapt, Zejula, Zytiga) | 80.98 | 91.45 | 48.59 |
Ophthalmology (Omidria, Eylea I+II) | 44.53 | 40.32 | 19.62 |
Hematology (Casgevy, Vonjo I+II) | 19.80 | 19.14 | 12.29 |
Neurology (Spinraza) | 14.75 | 15.16 | 7.35 |
Immunology (Xolair, Ekterly) | 10.66 | 13.43 | 9.19 |
Hematology/Ophthalmology (Empaveli/Syfovre) | 6.27 | 4.93 | 1.31 |
Dermatology (Oracea) | 7.41 | 4.65 | 1.85 |
Lysosomal storage disorder (Xenpozyme) | 1.47 | 4.42 | 3.33 |
Endocrinology (Natpara) | 2.09 | 1.04 | 0.00 |
Other products | 2.03 | 1.92 | 1.28 |
Total cash receipts | 189.99 | 196.44 | 104.81 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Revenue
| Therapeutic area | FY2025 share of cash receipts (%) | YoY growth FY2025 vs FY2024 (%) |
|---|---|---|
Oncology | 46.6 | 12.9 |
Ophthalmology | 20.5 | -9.5 |
Hematology | 9.7 | -3.3 |
Neurology | 7.7 | 2.8 |
Immunology | 6.8 | 26.0 |
Empaveli/Syfovre | 2.5 | -21.3 |
Dermatology | 2.4 | -37.2 |
Lysosomal storage disorder | 2.2 | 199.5 |
Endocrinology | 0.5 | -50.5 |
Other | 1.0 | -5.8 |
Royalty asset (Cash receipts, USD Mn)
| Royalty asset (Cash receipts, USD Mn) | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|
Orserdu I | 27.89 | 32.57 | 24.88 |
Orserdu II | 37.68 | 47.63 | 18.58 |
Omidria | 37.73 | 34.12 | 17.03 |
Spinraza | 14.75 | 15.16 | 7.35 |
Xolair | 10.66 | 12.61 | 5.20 |
Vonjo I | 12.20 | 11.52 | 5.99 |
Vonjo II | 7.60 | 2.62 | 1.30 |
Casgevy | 0.00 | 5.00 | 5.00 |
Eylea I | 5.60 | 5.10 | 2.14 |
Eylea II | 1.21 | 1.10 | 0.45 |
Empaveli/Syfovre | 6.27 | 4.93 | 1.31 |
Oracea | 7.41 | 4.65 | 1.85 |
Xenpozyme | 1.47 | 4.42 | 3.33 |
Zejula | 3.90 | 3.94 | 2.01 |
Zytiga | 6.05 | 3.76 | 1.76 |
Rydapt | 5.46 | 3.55 | 1.36 |
Ekterly | 0.00 | 0.82 | 3.99 |
Natpara | 2.09 | 1.04 | 0.00 |
Other products | 2.03 | 1.92 | 1.28 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total income (USD Mn) | 81.8 | 93.0 | 166.3 | 186.7 | 198.6 |
Royalty income (USD Mn) | 79.9 | 87.3 | — | — | 188.9 |
Total Cash Receipts, non-GAAP (USD Mn) | 115.6 | 96.2 | — | 190.0 | 196.4 |
Adjusted EBITDA, non-GAAP (USD Mn) | — | 82.4 | 113.2 | 156.6 | 165.0 |
EBITDA per IFRS reconciliation (USD Mn) | — | — | — | 148.6 | 112.3 |
Amortization of intangible royalty assets (USD Mn) | — | — | — | 102.9 | 101.7 |
Impairment of intangible royalty assets (USD Mn) | — | — | — | 15.8 | 23.4 |
Management fees (USD Mn) | — | — | — | 11.4 | 6.7 |
Interest expense (USD Mn) | — | — | — | 34.9 | 39.7 |
Pre-tax income (USD Mn) | — | — | — | -3.4 | -51.0 |
Net earnings (USD Mn) | 21.6 | 11.6 | — | -3.4 | -50.5 |
Comprehensive earnings (USD Mn) | 21.6 | 11.6 | 91.2 | -2.7 | -51.1 |
EPS basic (USD) | 0.62 | 0.30 | 2.08 | -0.06 | -0.91 |
EPS diluted (USD) | 0.62 | 0.30 | 2.07 | -0.06 | -0.91 |
Adjusted Cash EPU basic (USD) | 1.85 | 1.87 | 2.53 | 2.18 | 2.26 |
Distributions declared per unit (USD) | 0.3867 | — | — | — | 0.40 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Adjusted EBITDA margin on cash receipts (%) | 87 | 86 | — | 82 | 84 |
Net margin on total income (%) | 26.4 | 12.5 | 54.8 | -1.8 | -25.4 |
Total income YoY growth (%) | — | 13.7 | 78.8 | 12.3 | 6.3 |
Adjusted EBITDA YoY growth (%) | — | — | 37.4 | 38.3 | 5.3 |
Income Statement and Margin Analysis (%)
| Metric (USD Mn) | Q1 2026 | Q2 2026 | H1 2025 | H1 2026 |
|---|---|---|---|---|
Total income | 48.6 | 50.1 | 88.2 | 98.7 |
Total Cash Receipts | 58.4 | 46.5 | 102.1 | 104.8 |
Adjusted EBITDA | 52.8 | 42.6 | 82.0 | 95.3 |
Adjusted EBITDA margin (%) | 90 | 92 | 80 | 91 |
Net earnings | -1.0 | 6.0 | -1.4 | 5.0 |
Adjusted Cash EPU basic (USD) | 0.68 | 0.56 | 0.95 | 1.24 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansKey Financials and Operating Metrics (M)
| Metric | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
Cash and equivalents (USD Mn) | — | — | — | 42.4 |
Intangible royalty assets, net book value (USD Mn) | — | 518.1 | — | 777.8 |
Financial royalty assets (USD Mn) | — | — | 57.5 | 57.3 |
Credit facility principal (USD Mn) | — | — | — | 381.0 |
Preferred securities principal (USD Mn) | — | — | — | 108.9 |
Total debt principal (USD Mn) | — | — | — | 489.9 |
Net debt (USD Mn) | — | — | — | 447.5 |
Units outstanding at year end (M) | 40.1 | — | — | 55.07 |
Dividends & Capital Returns
| Metric (USD Mn) | FY2021 | FY2022 | FY2025 |
|---|---|---|---|
Distributions declared | 15.2 | 11.5 | 22.2 |
Unit buybacks (NCIB) | 5.5 | 7.3 | 14.2 |
Capital deployed in royalties | 292.7 | 281.0 | 87.0 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2024 | FY2025 |
|---|---|---|
Adjusted EBITDA / interest expense (x) | 4.5 | 4.2 |
Net debt / Adjusted EBITDA (x) | — | 2.7 |
Adjusted EBITDA margin (%) | 82 | 84 |
Royalty Base Details
| Royalty base | Assets |
|---|---|
U.S. net sales only | Omidria (2024 expansion covers U.S. sales), Lumvoa and elegrobart (U.S.), Juvmo (U.S.) |
Licence-fee based (not sales-geography based) | Casgevy (Vertex licence fees payable to Editas) |
Trend Details
| Trend | Asset | FY2025 vs FY2024 |
|---|---|---|
Fastest-growing | Xenpozyme | Up 200% |
| — | Orserdu II | Up 26% |
| — | Xolair | Up 18% |
| — | Orserdu I | Up 17% |
Declining | Natpara | Down 51% |
| — | Oracea | Down 37% |
| — | Zytiga | Down 38% |
| — | Rydapt | Down 35% |
| — | Vonjo II | Down 66% |
Capital Markets
| Item | Value (CAD) | Source |
|---|---|---|
IPO price | US$10.00 (February 2021) | IPO disclosure |
Price on July 8, 2024 (after the CEO exit) | C$11.17 | Globe and Mail |
Price on July 10, 2024 | C$12.27 | Stockwatch |
Price on October 3, 2024 | C$13.24 | Stockwatch |
Recent (mid-September 2026) | About C$16.91 | — |
52-week range | C$14.10 – C$19.75 | Third-party aggregator |
Valuation Multiples
| Multiple | Approximate value | Basis |
|---|---|---|
EV/Adjusted EBITDA (FY2025) | About 6.8x | Market cap of about $0.67B plus FY2025 net debt of $0.45B, against $165M |
Price / Adjusted Cash EPU (FY2025) | About 5.4x | About US$12.2 against $2.26 |
Distribution yield | About 3.3% | Third-party aggregator figure |
Quarterly Distribution by Period
| Period | Quarterly distribution (USD per unit) |
|---|---|
Q3 2021 and earlier | 0.0375 |
Q4 2021 | 0.075 (plus a 0.22 special) |
| 2025 | 0.10 |
| 2026 | 0.11 |
Capital Programmes
| Programme | Activity |
|---|---|
| 2,025 | 1,449,249 units repurchased for $14.2M at an average of $9.82 (USD line) |
2026 NCIB | Up to 3,060,594 units. 89,513 units repurchased in Q2 2026 for $1.0M. |
Capital Instruments
| Instrument | Principal | Coupon | Maturity |
|---|---|---|---|
Senior Secured Notes tranche 1 | US$106M | 5.35% | 2031 |
Senior Secured Notes tranche 2 | US$144M | 5.65% | 2033 |
Convertible debentures | C$108.7M | 5.75% | Feb 28, 2031 |
Remaining preferred securities | US$31.0M (carrying value, June 2026) | 7.50% (Series C) | — |
Credit facility (acquisition and working capital) | Drawn balance increased in July and September 2026 | Floating | — |
Analyst Conclusions
Management guidance
| Item | Guidance |
|---|---|
| FY2026 Adjusted EBITDA | $157M–$162M. Management expects to reach or exceed the high end; H1 2026 was already $95.3M. |
| H2 2026 margins | High-80s to 90% |
| 2026–2030 aspirations | $800M–$1,000M of deployment and a low-teens Adjusted EBITDA CAGR |
| Tavapadon | Management says it alone can deliver the 2030 Adjusted EBITDA aspiration without further acquisitions |
A formal sell-side consensus is not publicly available.
Bull case
-
The margin step-change is durable. Internalization lifted the Adjusted EBITDA margin from 76% to 92% in one year, and the carried-interest structure aligns the team with realized returns.
-
The pre-approval engine works. Three for three on FDA approvals (Ekterly, Lumvoa, Juvmo), plus one 1.5x exit, suggests repeatable alpha in underwriting.
-
Valuation is undemanding. The Trust trades at roughly 5–7x cash earnings and EBITDA, with contracted Juvmo fixed payments of $93.6M underpinning the downside.
Bear case
-
Concentration risk. Orserdu is about 41% of cash receipts. Any competitive or clinical setback there would cut cash flow sharply.
-
Leverage and execution. The $316M tavapadon deal, funded partly with debt, pushes leverage up just as Lumvoa's launch trajectory is unproven. Recent impairments (Vonjo II, Omidria) show that underwriting can miss.
-
Structural cost-of-capital disadvantage. Larger buyers can outbid DRI for the best assets, leaving it with riskier pre-approval or capped deals.
Catalysts and monitorables (next 12 months)
-
Q3 2026 results (expected November 2026): confirmation of tavapadon closing, pro forma leverage, and the Ekterly gain.
-
Lumvoa (veligrotug) launch trajectory and first royalty receipts.
-
Elegrobart (VRDN-003) regulatory progress and the remaining Viridian milestones.
-
Juvmo launch metrics. The first $23.4M fixed payment is due on or before September 25, 2027.
-
Orserdu sales versus competing oral SERDs.
-
The FY2027 guidance and distribution decision, expected around March 2027.
-
NCIB execution and any further capital recycling.
Concluding analyst verdict
DRI Healthcare Trust has emerged from a turbulent 2024 as a structurally better business. The Khosrowshahi resignation, the activist-style governance reset and the internalization were painful. But they removed about $11M a year of external fees, re-aligned incentives through a carried-interest plan, and handed control to a capital-markets-literate CEO in Ali Hedayat. The result is visible in the numbers: record FY2025 total income of $198.6M, and an Adjusted EBITDA margin that has climbed into the low 90s.
Capital allocation over the past 18 months has been well executed:
-
The Ekterly put returned 1.5x and a high-20s IRR.
-
Lumvoa secured FDA approval.
-
The Juvmo deal combines contracted fixed payments with royalty upside, under a hard cap that limits both risk and reward.
-
The March 2026 refinancing extended maturities to 2031–2033.
Management's claim that tavapadon alone underwrites its 2030 EBITDA aspiration is bold but not implausible, given the $93.6M of fixed payments.
The bear case is concentration and leverage. Orserdu supplied roughly 41% of FY2025 cash receipts, and recurring impairments on Vonjo II and Omidria are reminders that royalty underwriting is not infallible. Pro forma leverage after the $316M tavapadon outlay is not yet disclosed. It will be the key data point in the Q3 2026 release.
On a net view, DRI offers a high-cash-yield, catalyst-rich mid-cap royalty exposure at an apparent discount to larger peers. The combination of approximately 5–7x cash-flow multiples, a 3%+ distribution and a buyback programme gives investors patience capital.
Verdict: constructive, with position sizing tempered by single-asset concentration. Upside depends on successful Lumvoa and Juvmo launches and on disciplined redeployment of the expanded balance sheet. The Q3 2026 leverage print and early launch data are the critical near-term tests.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background |
|---|---|---|
Ali Hedayat | Chief Executive Officer | Trustee since at least 2023. Interim CEO of the manager from July 2024. CEO of DRI Healthcare after the 2025 internalization. Founder and Managing Director of Maryana Capital. Earlier: co-founder of Edoma Capital (2010–2012), partner at Indus Capital (2013–2015), and Goldman Sachs (1997–2010), including Managing Director and co-head of Americas Principal Strategies. Lead independent director of Restaurant Brands International. |
Navin Jacob | Chief Investment Officer | Led day-to-day investment execution through the 2024 leadership crisis, per a National Bank Financial note in July 2024. Leads underwriting, including tavapadon. |
Zaheed Mawani | Chief Financial Officer | Presented the Q2 2026 financials and is the contact on the September 2026 release. |
Bill Zhang | Head of Investor Relations | — |
Former: Amit Kapur | CFO (appointed August 2024) | — |
Former: Behzad Khosrowshahi | CEO (resigned July 8, 2024) | The board demanded his resignation during an investigation of alleged consulting and other expenses he submitted for reimbursement |
Executive Leadership Team — Gary Collins
| Name | Role / status |
|---|---|
Gary Collins | Chair. Interim CEO of the Trust from July 2024 until internalization (2025). |
Dr. Sheila Singh | Appointed August 7, 2026. Neurosurgeon-scientist and Head of the Comprehensive Cancer Centre at King's College London. |
Dr. Yasir Al-Wakeel | Appointed August 7, 2026. CEO of Vesalius Therapeutics, CEO-Partner at Flagship Pioneering, and formerly a biotech equity analyst. |
Kevin Layden | Resigned August 2026 (joined 2021) |
Ali Hedayat | Trustee and CEO |
Competitive Landscape
Key Competitors
| Competitor | Type | Positioning relative to DRI |
|---|---|---|
Royalty Pharma (Nasdaq: RPRX) | Public; largest royalty buyer | Far larger and lower cost of capital; dominates deals above $500M |
XOMA Royalty (Nasdaq: XOMA) | Public royalty aggregator | Smaller and earlier-stage; many milestone-type assets |
Ligand Pharmaceuticals (Nasdaq: LGND) | Public royalty and technology hybrid | Broader model, including Captisol and partnered programs |
HealthCare Royalty (HCRx) | Private | Direct competitor in the $50M–$500M range |
Blackstone Life Sciences | Private | Large synthetic-royalty and R&D funding |
Oberland Capital | Private | Structured royalty and debt |
Sagard Healthcare Royalty Partners | Private | Mid-market royalties |
OrbiMed Royalty and Credit | Private | Royalty and credit |
Bain Capital Life Sciences / NovaQuest | Private | Also sellers to DRI (tavapadon) |
Ares, Carlyle and structured-credit funds | Private | Hybrid royalty and debt |
Peer Comparison FY2025
| Metric | DRI Healthcare | Royalty Pharma | Ligand | XOMA Royalty |
|---|---|---|---|---|
Top line (definition varies) | 198.6 (total income) | 3254 (portfolio receipts) | 268.1 (total revenues and income) | 52.1 (income and revenues) |
Top-line growth YoY (%) | 6.3 | 16 | 60 | 83 |
Cash receipts metric | 196.4 | 3,254 | — | 50.5 |
Net income | -50.5 | — | — | 31.7 |
R&D intensity (%) | 0 | 0 | — | — |
2026 outlook | Adjusted EBITDA $157M–$162M | Portfolio receipts $3,275M–$3,425M | Royalty revenue $200M–$225M | — |



